Currently, several immune checkpoint inhibitors (ICIs), including anti-PD1 (nivolumab, pembrolizumab, and nivolumab plus ipilimumab) and anti-PD-L1 (atezolizumab, in combination with bevacizumab) therapies, have received FDA approval and provided new opportunities to treat advanced HCC (14). The gene discussed is CD274; the disease is hepatocellular carcinoma.